Literature DB >> 16373285

Octreotide in the treatment of refractory ascites of cirrhosis.

Georgios Kalambokis1, Andreas Fotopoulos, Michael Economou, Epameinondas V Tsianos.   

Abstract

Dietary sodium restriction and diuretic treatment have been shown to be effective in the treatment of ascites in the majority of cirrhotic patients. However, approximately 5 to 10% of patients develop refractory ascites, which is defined as ascites that does not respond to intensive diuretic therapy (diuretic-resistant) or ascites that cannot be controlled because the patient develops diuretic-induced complications that prevent the use of an effective diuretic dose (diuretic-intractable). Current therapeutic approaches for refractory ascites include repeated large-volume paracentesis and transjugular intrahepatic portosystemic shunting. In the present report, subcutaneous octreotide treatment improved renal function and hemodynamics and diuretic response in two patients with refractory ascites in line with a marked decrease in renin and aldosterone secretion. We consider that octreotide could be of value in the management of refractory ascites in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16373285     DOI: 10.1080/00365520510024043

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  3 in total

1.  Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites.

Authors:  Achuthan Sourianarayanane; David S Barnes; Arthur J McCullough
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-02

Review 2.  Evaluation and management of patients with refractory ascites.

Authors:  Bahaa Eldeen Senousy; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

3.  Systemic hemodynamic and renal effects of midodrine and octreotide in cirrhotic patients with ascites.

Authors:  Georgios N Kalambokis; Epameinondas V Tsianos
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.